Learning Objectives:

1. Understand challenges in drugging large protein-protein interactions.

2. Understand how combination therapies can widen the therapeutic window if delivered to the target cells simultaneously.

3. Understand how drugging the BCL-2 family of proteins may overcome cell death resistance in refractory malignancies

Session date: 
04/04/2022 - 12:00pm to 1:00pm CDT
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
James LaBelle, MD, PhD